RxDoctor Payments Data

Thomas Metkus, MD

Cardiovascular Disease · Philadelphia, PANPI 1619947116

Payments from drug & device makers

$12,858in general payments, 2019–2025

Across 141 payments — averaging $91.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BD$10K
  • Novartis$814
  • Medtronic$274
  • Impulse Dynamics (USA) Inc.$210
  • AstraZeneca$167
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$165
  • plus $1K from 22 others

What the payments were for

  • Consulting fees$10,00078%
  • Food & beverage$2,84022%
  • Education$180%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,858 in reported general payments places this provider in the 80th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$178,429
Medicare patients
1,149
Services billed
2,835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban136$152,045
XareltoRivaroxaban37$35,841
EntrestoSacubitril/Valsartan34$28,920
BrilintaTicagrelor29$24,471
FarxigaDapagliflozin Propanediol11$15,234
Metoprolol Succinate216$3,022
Atorvastatin Calcium176$2,201
ClopidogrelClopidogrel Bisulfate82$1,258
Furosemide150$1,078
Amlodipine Besylate174$1,052
Flecainide Acetate27$1,046
Losartan Potassium75$1,011
Rosuvastatin Calcium54$974
Carvedilol95$965
Nifedipine ErNifedipine33$805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$155$152,045136 claims
AstraZenecaBrilinta, Farxiga$167$39,70540 claims
Johnson & JohnsonXarelto$18$35,84137 claims
NovartisEntresto$814$28,92034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →